Attenuation of Brain Inflammatory Response after Focal Cerebral Ischemia/Reperfusion with Xuesaitong Injection(血塞通注射液) in Rats

Objective： To investigate the neuro-protective effect of Xuesaitong Injection （血塞通注射液, XST） on brain inflammatory response after transient focal cerebral ischemia/reperfusion in rats. Methods： Focal cerebral ischemia/reperfusion models of male rats were induced by transient occlusion for 2 h of middle cerebral artery （MCA） which was followed by 24 h reperfusion. XST was administered through intraperitoneal injection of 25 mg/kg or 50 mg/kg at 4 h after the onset of ischemia. After reperfusion for 24 h, the neurological function score was evaluated, the brain edema was detected with dry-wet weight method, the myeloperoxidase （MPO） activity and the expression of intercellular adhesion molecule-1 （IOAM-l） of ischemic cerebral cortex and caudate putamen was determined by spectrophotometry and immunohistochemistry respectively. Results： XST not only lowered neurological function score at the dose of 50 mg/kg, but reduced brain edema and inhibited MPO activity and IOAM-1 expression as compared with the ischemia/reperfusion model group （P〈0.01）. Conclusion： XST has a definite effect on inhibiting the expression of IOAM-1 and neutrophil infiltration in rats with cerebral ischemia/reperfusion when treatment started at 4 h after ischemia onset, and also attenuates inflammation in the infarcted cerebral area.     

RP—HPLC梯度洗脱法测定血塞通片中三七皂苷R1、人参皂苷Rb1及人参皂苷Rg1的含量

目的:用高效液相色谱梯度洗脱法同时检测血塞通片中三七皂苷R_1、人参皂苷Rb_1和人参皂苷Rg_1 3种皂苷的含量。方法:用Eclipse XDB—C_8分析柱;乙腈-水二元梯度洗脱;0—15 min(25:75—32:68),平衡5 min;流速1.0 mL·min~(-1);检测波长203 nm。结果:三七皂苷R1、人参皂苷Rg_1和人参皂苷Rb_1的线性范围分别为O.51-3.05,1.68—10.09,2.73—16.39μg。该方法回收率三七皂苷R_1为99.92%(RSD=0.70%)、人参皂苷Rg_1为98.93%(RSD=1.4%)、人参皂苷Rb_1为102.8%(RSD=0.81%)。结论:HPLC梯度洗脱法能将多种皂苷很好地分离检测,提高了时效,减少了误差,结果表明该方法准确可靠,重现性好,结果稳定。     

口服中成药治疗2型糖尿病周围神经病变的网状Meta分析

目的 运用网状Meta分析方法,评价临床常用口服中成药治疗2型糖尿病周围神经病变的有效性及安全性。方法 计算机检索中国知网（CNKI）、万方（Wanfang）、维普（VIP）、中国生物医学文献服务系统（CBM）、PubMed、Embase、Cochrane Library、Web of Science中有关中成药干预糖尿病周围神经病变的随机对照试验（randomized controlled trial,RCT）,时间跨度为建库至2022年11月10日;采用Cochrane偏倚风险评估工具对纳入研究进行质量评价;运用R 4.2.1进行网状Meta分析。结果 共纳入57项RCTs,总样本量5200例,涵盖10种口服中成药（木丹颗粒、银丹心脑通软胶囊、通心络胶囊、津力达颗粒、糖脉康颗粒、复方血栓通胶囊、复方丹参滴丸、通脉降糖胶囊、脑心通胶囊、血塞通胶囊）。在改善感觉神经传导速度方面,木丹颗粒+常规治疗（conventional treatment,CT）相对较优;在改善运动神经传导速度方面,通心络胶囊+CT相对较优;在改善氧化应激反应方面,木丹颗粒+CT、复方血栓通胶囊+CT相对较优;在安全性方面,17项研究报道了共计17例不良反应发生,且试验组与对照组间无统计学差异（P＞0.05）。结论 相比于常规治疗,在其基础上联用中成药治疗2型糖尿病周围神经病变在改善周围神经功能和氧化应激反应方面均有优势,其中木丹颗粒+CT各项疗效结局指标均优于对照组（P＜0.05）,排名相对靠前,且安全性较高,可能为最佳治疗方案,但由于不同干预措施纳入研究质量和方法学的局限性,所得结论尚需进一步验证。     

血塞通注射液治疗慢性呼吸衰竭的临床观察

目的:观察中药制剂血塞通注射液治疗慢性呼吸衰竭的临床疗效.方法:将86例慢性呼吸衰竭患者随机分为两组,对照组单用西医常规治疗,观察组在西医常规治疗的基础上加用血塞通注射液静脉滴注,两组疗程均为2周.结果:观察组总有效率81.3%,与对照组(72.1%)相比,P＜0.05,在改善血气分析及血液流变学指标方面明显优于对照组.结论:中药血塞通注射液治疗慢性呼吸衰竭疗效肯定.     

血塞通注射液治疗早期脑梗塞的疗效观察

目的:探讨血塞通注射液(三七总苷)治疗脑梗塞的疗效.方法:病人60例,随机分为二组,血塞通组30例,用血塞通10mL(0.5g)加入0.9%盐水250mL静脉滴注.丹参组30例,用丹参16mL加入0.9%盐水250mL静脉滴注,每日1次,二组疗程均为28d.结果:血塞通组总有效率80.0%,不良反应少,丹参组总有效率66.7%,组间经轶和分析,治疗组明显优于对照组(P＜0.05).结论:血塞通,它可使血小板聚集力和粘附力降低并具有溶栓作用,对早期脑梗塞的治疗效果较好.     

Effect of Xuesaitong Soft Capsule(血塞通软胶囊)on Hemorrheology and in Auxiliarily Treating Patients with Acute Cerebral Infarction

Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊,XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group ( n = 96) and the treated group ( n = 108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrhe.ological indexes were measured before and after treatment. Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group (66.7%) was significantly higher than that in the control group (27.1%, P＜0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 inthem evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.     

血塞通对急性冠脉综合征C-反应蛋白水平的影响

急性冠脉综合征（acute coronary syndrome，ACS）是冠状动脉粥样硬化斑块不稳定、破裂、出血及血栓形成所致冠状动脉管腔完全或不完全闭塞引起的临床上以急性心肌梗死和不稳定心绞痛为表现的综合征。越来越多ACS的研究证实，动脉粥样硬化不是简单的脂质沉积过程，局部或全身慢性炎症在粥样硬化斑块的发生、发展中也起重要作用。     

指纹图谱测定注射用血塞通、血栓通注射液及注射用血脉通的化学成分

目的 研究注射用血塞通、血栓通注射液及注射用血脉通的化学成分,为注射用血脉通立项提供实验依椐.方法 用symetry shield C18色谱柱(250 mm ×4.6 mm,5 μm);流动相为乙腈-水二元梯度洗脱;流速1.0 ml·min-1;分别以ELSD和UVD为检测器,ELSD测定参数为漂移管温度115 ℃;气体(氮气)流量1.5 L·min-1,检测波长210 nm.在此色谱条件下,将3种药品的主要组分分别展开,表达成色谱指纹图谱,并对主组分进行结构识别,归属跟踪,对各自的有效成分进行了分析和比较.结果 注射用血塞通、血栓通注射液均为三七的总皂苷,有效成分基本相似,仅存在组成比例波动,其主要差别是剂型不同;注射用血脉通的主组分为三七三醇皂苷,与前两制剂的物质基础存在较大差异.结论 通过指纹图谱可以对三七及其制剂的有效成分进行测定.     

血塞通注射液与银杏叶制剂联合治疗糖尿病视网膜病变

目的：观察血塞通注射液与银杏叶制剂联合治疗糖尿病视网膜病变的疗效。方法：血塞通400mg，溶于氯化钠注射液250ml中静脉点滴，每天一次，14天为一个疗程，休息5—7天，再进行第二个疗程，治疗两个疗程。同时给予银杏叶胶囊2片，每日3次。结果：本组病例38例（42只眼），显效：22只眼，占52．38％，有效：15只眼，占35．74％，无效：5只眼，占11．90％，总有效率为88．10％。结论：血塞通注射液与银杏叶制剂联合治疗糖尿病视网膜病变安全、有效，特别是对增殖型Ⅳ期、Ⅴ期视网膜病变的患者，促进玻璃体积血尽快吸收，为顺利实施激光光凝治疗赢得了时间。     

血塞通滴丸抗大鼠血栓形成及溶栓作用的实验研究

目的:研究血塞通滴丸抗血栓、溶栓作用,并从该药对血液流变性的影响初步分析其作用机制。方法:大鼠随机分为5组,空白对照组,血塞通滴丸90,30,10 mg.kg-13个剂量组,血塞通片30 mg.kg^-1组,运用动静脉环路法测定血塞通滴丸对大鼠旁路血栓形成的影响;大鼠随机分为7组,模型组,血塞通滴丸90,30,10 mg.kg^-13个剂量组,血塞通片90,30 mg.kg^-1组,蚓激酶胶囊组,以颈总动脉温度测定法测定血塞通滴丸对大鼠总动脉血栓形成后的溶栓作用;大鼠随机分为6组,空白对照组,模型组,血塞通滴丸80,40 mg.kg^-12个剂量组,血塞通片40,20 mg.kg-12个剂量组,以急性应激大鼠模型观察血塞通滴丸对其血液流变学的影响。结果:血塞通滴丸90,30 mg.kg^-1可使血栓湿重和干重明显下降(P<0.01),且剂量之间显示出一定的量-效关系。血塞通滴丸90mg.kg-1有明确的溶栓作用(P<0.01)。血塞通滴丸80,40,20 mg.kg-1对红细胞聚集性有明显的降低作用(P<0.01),对低切全血黏度有一定的降低作用(P<0.05)。80,40 mg.kg-1血塞通滴丸分别对中切黏度和血浆黏度有一定的降低作用(P<0.05)。80 mg.kg-1血塞通滴丸分别对高切黏度有一定的降低作用(P<0.05)。结论:血塞通滴丸具有较好的抗血栓与溶栓作用,其对血液流变性的影响是抗血栓与溶栓的作用机制之一。